NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Anita M. Engh(Ithaka Harbors), Luciano J. Costa(University of Alabama at Birmingham), Griselda Zuccarino-Catania(Pancreatic Cancer Action Network), Suzanne McGettigan(University of Pennsylvania), Stephanie Andrews(Moffitt Cancer Center), Julie R. Brahmer(Johns Hopkins University), Ryan Weight(University of Colorado Cancer Center), Bryan J. Schneider(Georgetown University), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David Dunnington(Roswell Park Comprehensive Cancer Center), Marianne Davies(Smilow Cancer Hospital), Olalekan O. Oluwole(Vanderbilt University), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Jordan P. McPherson(University of Utah), Philippe Armand(Harvard University), Alyse Johnson-Chilla(National Comprehensive Cancer Network), Matthew J. Frigault(Harvard University), Nisha Mohindra(Fox Chase Cancer Center), Sandip Pravin Patel(University of California San Diego), Mabel Ryder(Mayo Clinic in Arizona), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Anthony J. Olszanski(Fox Chase Cancer Center), Benjamin H. Kaffenberger(The Ohio State University Wexner Medical Center), Lihua E. Budde(City Of Hope National Medical Center), Matthew A. Lunning(University of Nebraska Medical Center), Marc S. Ernstoff(National Cancer Institute), Yinghong Wang(Hangzhou Center for Disease Control and Prevention), Sunil Reddy(Cancer Institute (WIA)), Bianca Santomasso(Georgetown University), Scott Shofer(Cancer Institute (WIA)), Nathan A. Pennell(Cleveland Clinic)
Cited by 484
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k